Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TDS

TransPerfect Life Sciences to Lead Collaboration Workshop and Release New Trial Interactive E-Clinical Technology at DIA 2018


BOSTON, June 19, 2018 /PRNewswire/ -- TransPerfect Life Sciences, a leading provider of services and technologies to support global product development for the life sciences industry, today announced highlights of its presence at DIA 2018, including a workshop entitled Real-Life Strategies for Collaborative Stakeholder Management as well as the release of version 9.2 of the award-winning Trial Interactive e-clinical platform.

TP Life Sciences

The workshop will be held June 27 at 2:00 PM and will be led by Christine Morris, Executive Director of TransPerfect Life Sciences. She will share her expert actionable insights and real-world stories in a forum exploring ideas and methods that can be used by study teams to increase collaboration with targeted (role- and theme-/type-specific) strategies. 

In addition, TransPerfect will be highlighting the newest release of its award-winning e-clinical platform, Trial Interactive 9.2. This cloud-based solution was designed by clinical professionals for clinical professionals to address real-world needs of clinical operations, regulatory, and quality assurance, and to reduce administrative challenges while lowering compliance risks.

New Developments on Display

Trial Interactive 9.2 ? New enhancements to the Trial Interactive e-clinical platform include a Universal Viewer with powerful document review and comparison capabilities, an enhanced Trial Correspondence Inbox for real-time email correspondence capture and attachment rendering, a new, built-in 21 CFR Part 11-, Annex 11-, and ERES-compliant e-signature solution, and optional multi-factor authentication, along with other important features that are helping study teams stay inspection-ready and streamline TMF document processes.

myTI ? Trial Interactive now goes wherever you go?see a demo of the myTI mobile platform that provides study teams with mobile document capture capabilities, real-time document work streams, and completeness insights?anytime and anywhere. Version 1.1 is available to TI users on the Google Play and Apple Stores.

GlobalLearn ? Trial Interactive's learning management system (LMS) is here. GlobalLearn is a compliance-focused LMS that allows you to train and certify study teams on study protocol, regulatory, and SOP compliance, expediting training timelines and reducing compliance risks while increasing operational excellence.

The Trial Interactive Platform
Trial Interactive is a diversified solution that streamlines multiple aspects of the product development lifecycle. Demos are available at DIA Booth #1602 for all modules, including:

Trial Interactive is consistently praised by clinical professionals as the most comprehensive e-clinical platform, covering a wide range of functional areas in a single, intuitive platform with powerful workflows that accelerate site activation and ensure compliant study teams, while reducing study timelines, costs, compliance risks, and administrative burdens. Contact [email protected] for more information.

About TransPerfect Trial Interactive
TransPerfect's Trial Interactive solution provides a collaborative web-based platform for study start-up and eTMF that enables sponsors, CROs, IRBs, central laboratories, and other vendors to maintain and update clinical trial documentation in a secure online environment. Trial Interactive streamlines study timelines and reduces the administrative burdens of global clinical trials. As part of TransPerfect's Life Sciences division, Trial Interactive is dedicated to working collaboratively  with clients on a global scale, supporting the clinical trial life cycle with platform offerings including investigator database, e-feasibility, study start-up, eTMF and TMF management services, mobile eTMF, clinical document management and collaboration, compliance-focused learning management, pharmacovigilance and safety management, endpoint adjudication, and product licensing and alliance management.

For more information on Trial Interactive, please contact [email protected] or +1 212.400.8848, or visit www.trialinteractive.com.

About TransPerfect
TransPerfect is the world's largest provider of language services and technology solutions for global business. From offices in over 90 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 4,000 global organizations employ TransPerfect's GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com.

SOURCE TransPerfect


These press releases may also interest you

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug...

at 08:00
Human Immunology Biosciences (HI-Biotm), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that two abstracts have been accepted for oral presentation at the...

at 08:00
PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort® utilizing its...



News published on and distributed by: